What is the market size for pain relief medication ?

 

Pain Relief Medication Market Highlights

Pain relief medicine is a branch of medicine that employs an interdisciplinary approach for easing the suffering and improving the quality of life of those living with acute as well as chronic pain.

The growth of the global pain relief medication market overview is driven by several factors such as increasing patient population suffering from chronic pain and cancer pain, increasing research in the pain management field, and rising product launch in the pain relief medication market. However, the stringent regulations and high cost of drugs are likely to hamper the growth of the global pain relief medication market.

Several market players currently dominate the global pain relief medication market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in July 2018, AbbVie received approval for Orilissa (elagolix) from the US Food and Drug Administration (FDA) for the management of moderate to severe pain associated with endometriosis.

According to MRFR analysis, Pain Relief Medication Market Size is expected to register a CAGR of 7.22% during the forecast period of 2022 to 2030 and held a value of 1,62,175.20 Million in 2030.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East Africa. The Americas are expected to be the largest market owing to the rise in chronic diseases in this region. In Brazil, chronic pain is a widespread clinical condition, affecting between 28% and 41% of the Brazilian population. The pain relief medication market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European pain relief medication market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The pain relief medication market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rise in initiatives by public and private organizations, the market in Asia-Pacific is expected to be the fastest-growing. The pain relief medication market in the Middle East Africa has been divided into the Middle East and Africa.

Segmentation

The global pain relief medication market has been segmented based on drug class, indication, and distribution channel.

The market, based on drug class, has been divided into nonsteroidal anti-inflammatory drugs, opioids, COX-2 inhibitors, and others. The nonsteroidal anti-inflammatory drug segment is likely to be the largest during the review period due to the high efficacy rate of this drug class. The opioids segment is predicted to be the fastest-growing due to the increasing awareness about the drugs in this class in the pain relief medication market.

The global pain relief medication market has been segmented based on the indication, into cancer pain, neuropathic pain, musculoskeletal pain, inflammatory conditions, and topical foot pain relief. The cancer pain segment is expected to hold the majority share of the market owing to the increasing people suffering from this type of pain. The neuropathic pain segment is expected to be the fastest-growing due to the rising patient population in different economies.

The global pain relief medication market, by distribution channel, has been divided into hospital and retail pharmacies, and online pharmacies. The hospitals and retail pharmacies segment are projected to hold the largest share of the market due to the increasing number of hospitals in-visits. The online pharmacies segment is expected to be the fastest growing owing to the rise in the awareness about online distribution network.

Key Players

Some of the key players in the global pain relief medication market are AbbVie Inc. (US), Allergan plc (Ireland), Astellas Pharma Inc. (Japan), Bayer (Germany), Biogen Idec (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb (US), Eli Lilly and Company (US), GlaxoSmithKline (UK), Mallinckrodt Pharmaceuticals (UK), Pfizer, Inc. (US), Purdue Pharma (US), Sanofi (France), and Teva Pharmaceutical Industries Ltd (Israel).

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Cardiac Monitoring and Cardiac Rhythm Management Device Market Growth Opportunities, Demand and Forecasts, 2020-2027

  Market Highlights The increasing demand for minimally invasive surgeries drives the growth of this market. Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also led to growth in this market.  However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market. Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the  cardiac monitoring and cardiac rhythm management device market . Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. Segmentation The global cardiac monitoring and  card...
Read more

Cancer Biological Therapy Market Demand, Business Strategies, Current Trends And Efficient Techniques, Forecast 2030

  Market Highlights Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. These various types of biological therapies, which are most of the times stated to biological modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are also other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies. Cancer Biological therapy market  treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such c...
Read more

Medical Imaging Software Market SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2022-2030

  Medical Imaging Software Market Highlights Medical imaging software supports processing and producing high-resolution images of the internal body parts of a human for disease diagnosis and treatment. The emergence of 3D and 4D imaging technologies, increasing the prevalence of geriatric population and subsequent growth in the incidence of cardiac, and neurological diseases including cancer, growing government funding’s for development of medical diagnostics field are some factors that are anticipated to drive the market growth during the assessment period.  Additionally, a rise in the number of diagnostic centres and increased healthcare expenditure is likely to contribute to market growth. As per the data by the Office for National Statistics, in 2016, the gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in the UK. However, the high cost of equipment related to clinical validation and lack of skilled professionals m...
Read more